Prediabetes is a serious health condition affecting more than 1 in 3 U.S. adults - that's 88 million people - but most people don't know they have it. People who have prediabetes have a 50% chance of developing diabetes over the next 5 to 10 years.
read full article ›In the first physical meeting for many of us, a well-attended AVBCC saw Day 1 panelists — payers, oncology groups, pharmas — virtually universally predict that now-rare oncology VBAs between payers and pharmas will dramatically multiply within the next two years, specifically in cell/gene therapy and PD-1/PD-L1 antibodies.
read full article ›Depression is a leading cause of disability worldwide and is a major contributor to the overall global burden of disease. It is estimated that 5% of adults suffer from depression. But despite the universal nature and magnitude of mental ill health, there are still serious gaps that exist in mental health care, with relatively few people around the world having access to quality mental health services.
read full article ›On a recent trip to Cambridge to visit clients (yes, we are happily doing that again), we were struck by Henri Termeer’s words and the realization of what Cambridge has become. More than just the cradle of biotech, Cambridge has become home to countless dreamers and doers focused on conquering rare genetic diseases and conditions long-thought incurable or untreatable.
read full article ›Study highlights some eye opening data around disparities and discrimination in healthcare delivery. To think of vulnerable patients facing such barriers to equitable care is distressing to say the least. Equally unconscionable is the idea that income and an inability to pay continues to represent such a barrier to equitable access. Solutions are long overdue to level the playing field in making healthcare access a right for all.
read full article ›Excited to see the innovation and leadership Prime Therapeutics and Pear Therapeutics are embodying to facilitate patient access to PDTs through well-partnered Value Based Agreements. Payers and manufacturers can hopefully follow a similar path to develop value based approaches that expand access to life changing treatments for patients.
read full article ›While the development of durable cell and gene therapies represents extraordinary clinical value, the practical issues of financing cures continue to stand as an impediment to implementation. Will new payment approaches be an effective solution or will legislative issues, like MBP stand in the way of innovation and cures?
read full article ›An interesting perspective on how a community oncology practice did the unexpected – drove biosimilar utilization in oncology!
read full article ›Physician groups look to CMS to reverse the 2019 regulation allowing step therapy in Medicare Part B – implications of this change could be dramatic, especially with biosimilar utilization increasing under physician buy-and-bill models. Do you think physician groups would be willing to trade a flat admin fee in return for the end of step-edits…
read full article ›